Companies › Stealth BioTherapeutics
1 active drug program in 2 registered trials: 1 Phase 4, 1 Phase 3; Metabolic and endocrine, Ophthalmology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Elamipretide OPA1-targeted peptide; mitochondrial function enhancer | OPA1 | Phase 4 | Barth Syndrome; Age Related Macular Degeneration (ARMD) | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06373731 | Elamipretide | Phase 3 | Age Related Macular Degeneration (ARMD) | Ophthalmology | Aug 2027 |
| NCT07531251 | Elamipretide | Phase 4 | Barth Syndrome | Metabolic and endocrine | Sep 2029 |
Ascendis Pharma Bone Diseases BioXTek HealthTech Wound Care PolarityTE Royal Biologics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.